hydroxychloroquine + chloroquine + CAB

This is a combination drug consisting of hydroxychloroquine, chloroquine, and an unspecified component abbreviated as "CAB." Hydroxychloroquine and chloroquine are both 4-aminoquinoline compounds primarily used as antimalarial agents. They are also indicated for autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Both drugs act by interfering with lysosomal activity and autophagy, modulating immune system signaling, and inhibiting heme polymerase in malaria parasites. Their mechanisms include increasing the pH within intracellular vacuoles, which disrupts parasite development in red blood cells and alters immune cell function. The abbreviation "CAB" is not a standard or recognized pharmaceutical ingredient in this context; without further specification it cannot be described here.